- Home
- NRIX vs SGML Comparison
NRIX vs SGML Comparison
Compare NRIX & SGML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- SGML
- Stock Information
- Founded
- NRIX 2009
- SGML 2011
- Country
- NRIX United States
- SGML Brazil
- Employees
- NRIX N/A
- SGML N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- SGML Industrial Machinery/Components
- Sector
- NRIX Health Care
- SGML Industrials
- Exchange
- NRIX Nasdaq
- SGML Nasdaq
- Market Cap
- NRIX 750.4M
- SGML 743.4M
- IPO Year
- NRIX 2020
- SGML N/A
- Fundamental
- Price
- NRIX $16.85
- SGML $9.75
- Analyst Decision
- NRIX Strong Buy
- SGML Strong Buy
- Analyst Count
- NRIX 14
- SGML 2
- Target Price
- NRIX $26.29
- SGML $13.00
- AVG Volume (30 Days)
- NRIX 1.8M
- SGML 9.9M
- Earning Date
- NRIX 10-09-2025
- SGML 11-14-2025
- Dividend Yield
- NRIX N/A
- SGML N/A
- EPS Growth
- NRIX N/A
- SGML N/A
- EPS
- NRIX N/A
- SGML N/A
- Revenue
- NRIX $83,687,000.00
- SGML $138,959,151.00
- Revenue This Year
- NRIX $58.48
- SGML $31.25
- Revenue Next Year
- NRIX N/A
- SGML $46.46
- P/E Ratio
- NRIX N/A
- SGML N/A
- Revenue Growth
- NRIX 48.32
- SGML N/A
- 52 Week Low
- NRIX $8.18
- SGML $4.25
- 52 Week High
- NRIX $23.09
- SGML $14.71
- Technical
- Relative Strength Index (RSI)
- NRIX 80.15
- SGML 68.24
- Support Level
- NRIX $12.43
- SGML $5.29
- Resistance Level
- NRIX $13.43
- SGML $11.72
- Average True Range (ATR)
- NRIX 0.97
- SGML 0.97
- MACD
- NRIX 0.32
- SGML 0.51
- Stochastic Oscillator
- NRIX 98.68
- SGML 71.33
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.